The PPI innovation grant is specifically aimed at supporting researchers to use innovative and ground-breaking approaches to involve patients and the public in their research and/or to involve seldom heard groups in research.
View this resource Bookmark this resourceGrant
The Innovative Health Initiative Joint Undertaking (IHI JU) is a partnership between the European Union
and industry associations representing the sectors involved in healthcare, namely COCIR (medical
imaging, radiotherapy, health ICT and electromedical industries); EFPIA, including Vaccines Europe
(pharmaceutical industry and vaccine industry); EuropaBio (biotechnology industry); and MedTech
Europe (medical technology industry).
IHI JU aims to pioneer a new, more integrated approach to health research and builds on the experience
gained from the Innovative Medicine Initiative 2 Joint Undertaking (IMI2 JU).
IHI JU aims to translate health research and innovation into real benefits for patients and society, and
ensure that Europe remains at the cutting edge of interdisciplinary, sustainable, patient-centric health
research. Health research and care increasingly involve diverse sectors. By supporting projects that bring
these sectors together, IHI JU will pave the way for a more integrated approach to health care, covering
prevention, diagnosis, treatment, and disease management.
As current health challenges and threats are global, IHI JU should be open to participation by
international academic, industrial and regulatory actors, in order to benefit from wider access to data and
expertise, to respond to emerging health threats and to achieve the necessary societal impact, in
particular improved health outcomes for Union citizens.
Transnational Research Projects on Bidirectional Brain-Body Interactions
Published by ERA-NET NEURON
NeuronMaintenance, improvement, and restoration of human brain health are of fundamental importance and a worldwide priority. It has become increasingly evident that bidirectional communication between the central nervous system and the body has significant implications for maintaining both homeostatic and brain function. Abnormalities in brain–body interaction linked to genetic, environmental or lifestyle factors encompass a wide range of conditions affecting millions worldwide. Dysregulation of the brain-body axis can potentially contribute to or exacerbate various neurological and psychiatric disorders. The estimated prevalence can vary significantly depending on factors such as geographic location, population demographics, and advancements in medical diagnosis.
The study of bidirectional interactions between the central nervous system and the body is an emerging field of research that holds the potential to enhance our understanding of often overlooked pathophysiological processes involved in common neurological and psychiatric disorders. Expanding our current knowledge in this area is crucial as it serves as the initial step towards the development of therapeutic and preventive approaches aimed at preserving and improving brain health on a global scale.
The ‘Network of European Funding for Neuroscience Research’ (NEURON) has been established under the ERA-NET scheme of the European Commission (www.neuron-eranet.eu). The ERA-NET NEURON aims to coordinate and optimize research efforts and funding programmes of its partner countries/regions in the field of mental, neurological, and sensory disorders. Under the umbrella of NEURON, a joint transnational call (JTC 2024) in the field of bidirectional brain-body interactions is launched in 2024.
View this resource Bookmark this resourceSize of ERC Proof of Concept GrantsThe financial contribution will be awarded as a lump sum of EUR 150 000 for a period of 18 months. The ERC expects that normally proof of concept activities should be completed within 12 months. However, to allow for those projects that require more preparation time, the grant agreements will be signed for 18 months. Extensions of the duration of proof of concept projects may be granted only exceptionally.
The lump sum will cover the beneficiaries’ direct and indirect eligible costs for the project: if the project is implemented properly the amounts will be paid regardless of the costs actually incurred. The lump sum has been designed to cover the beneficiaries’ personnel costs, subcontracting, purchase costs, other cost categories and indirect costs.
View this resource Bookmark this resource
NeuroNEXT Small Business Innovation in Clinical Trials (U44 Clinical Trial Optional)
Published by NIH
Clinical TrialInvestigational Medicinal ProductRare diseasesThis Funding Opportunity Announcement (FOA) encourages small business applications for exploratory clinical trials of investigational agents (drugs, biologics, surgical therapies or devices) that may contribute to the justification for and provide the data required for designing clinical studies. Diseases chosen for study should be based on the NINDS strategic plan and clinical research interests (www.ninds.nih.gov/funding/areas/index.htm).
Successful applicants will be given access to the NeuroNEXT infrastructure. Following peer review, NINDS will prioritize and order trials that are given access to the NeuroNEXT infrastructure. The NeuroNEXT Clinical Coordinating Center (CCC) will work with the successful applicant to efficiently implement the proposed study. The NeuroNEXT Data Coordinating Center (DCC) will provide statistical and data management support. The NeuroNEXT clinical sites will provide recruitment/retention support as well as on-site implementation of the clinical protocol.
Applicants do not need to be part of the existing NeuroNEXT infrastructure.
View this resource Bookmark this resource
Long-term access and preservation infrastructure development for EOSC, including data quality aspects
Published by European Commission (EC)
CloudOpen ScienceIn the digital and data driven paradigm promoted by Open Science, data is at the core of the scientific process and its production grows at ever increasing rates. The volume of data currently is many-fold larger compared to just two years ago. In science there are many intermediate data objects being created through the phases of research activities and they are managed within the research data lifecycle in which curation and preservation are key elements to make accessible data that are interoperable and reusable. Costs and physical limitations of storage and service capacity lead to the difficult question of what is worth long term preserving narrowing the selection to data and other digital objects that will have long-term benefits to science and society.
Coordination to harmonise practices and standards within and across the different scientific fields and adequate infrastructures are necessary to implement the level of curation and preservation needed and to offer the related services that differ in practice and effort per discipline ant type of data.
View this resource Bookmark this resource
NINDS Exploratory Clinical Trials for Small Business (R41/R42 Clinical Trial Required)
Published by NIH
Clinical TrialsRare diseasesSmall Business Innovation ResearchThe purpose of this funding opportunity announcement (FOA) is to provide a vehicle for Small Business Concerns (SBCs) submitting Small Business Innovation Research (SBIR) grant applications for investigator-initiated exploratory clinical trials to the National Institute of Neurological Disorders and Stroke (NINDS). The projects must focus on products related to the mission and goals of the NINDS and may evaluate drugs, biologics, devices, or diagnostics, as well as surgical, behavioral or rehabilitation therapies.
View this resource Bookmark this resource
Clinical Studies of Orphan Products Addressing Unmet Needs of Rare Diseases (R01) Clinical Trials Required
Published by NIH
Clinical TrialRare diseasesUnmet NeedsThe purpose of this funding opportunity announcement (FOA) is to fund clinical trials of products evaluating efficacy and/or safety in support of a new indication or change in labeling to address unmet needs in rare diseases or conditions. Additionally, through the funding of collaborative, efficient, and/or innovative clinical trials, FDA expects to increase the number of approved treatments for rare diseases and exert a broad and positive impact on rare disease drug development.
View this resource Bookmark this resource
HEAL INITIATIVE: Development of Therapies and Technologies Directed at Enhanced Pain Management (R43/R44 Clinical Trial Not Allowed)
Published by NIH
Pain ManagementScreening ToolsTherapies and TechnologiesThe purpose of this Funding Opportunity Announcement (FOA) aims to speed scientific solutions to stem the national opioid public health crisis by supporting the development of therapies and technologies directed at enhanced pain management through the Small Business Innovation Research (SBIR) program. This FOA is focused on applications directed at improving pain treatment, including the development of new non-addictive medications and devices and objective pain measurement. In addition, NIH is interested in new screening tools and models focused specifically on pain and development of pain therapies.
View this resource Bookmark this resource
Developing EU Methodological Frameworks for Clinical/Performance Evaluation and Post-market Clinical/Performance Follow-up of Medical Devices and In Vitro Diagnostic Medical Devices (IVDs)
Published by European Commission (EC)
ClinicMedical DeviceThis topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination 6 “Maintaining an innovative, sustainable and globally competitive health industry”.
View this resource Bookmark this resource